15/08/2025

EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

EMVISION AWARDED $3M NON-DILUTIVE GRANT FOR EMU REGIONAL BENEFITS STUDY

Key Highlights:

- **$3M non-dilutive Australian Government grant awarded to conduct studies in regional Australia, with the aim of improving stroke care through the use of telehealth-enabled emu™ point-of-care brain scanners.**
- **Study is the first to investigate the benefits of a novel stroke care workflow incorporating the telehealth-enabled emu™ scanner, aimed at accelerating time to scanning and diagnosis.**
- **Study data is intended to help drive emu™ product adoption and commercialisation.**
- **Partners in the project include Titan Pre-hospital Innovation, Australian Stroke Alliance and South Australian Rural Support Service.**
- **Funding available to EMVision from outstanding grants now totals $7.4m.**

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company") is pleased to announce it has been awarded $3m in non-dilutive grant funding under the Cooperative Research Centres Projects (CRC-P) Round 17 grant program.

The CRC-P is an Australian Government grant program, represented by Department of Industry, Science and Resources, that supports short-term, industry-led collaborative research projects.

This study conducted under the CRC-P grant will be invaluable in demonstrating the clinical benefit of EMVision's emu™ device, which is a central requirement for hospital and health network purchase decision making.

Project Aims

Stroke care related inequalities are most evident in Australia's regional, rural and indigenous communities. These communities often suffer from limited advanced medical imaging capabilities, alongside constraints in the 24/7 availability of on-site specialist staff, including radiographer, neurology and radiology services required to deliver timely stroke care.

Under this CRC-P project, a clinical study in South Australian regional hospitals will be conducted with EMVision's emu™ point-of-care brain scanners, enabled with telehealth (Titan Zeus) and dedicated stroke nurses, to demonstrate the ability to provide more timely diagnosis. Refining stroke care workflow and diagnostic capability in resource constrained communities represents an opportunity to greatly improve outcomes for these underserved patient populations.

This is the first study to demonstrate the benefit of the emu™ point-of-care brain scanner in clinical use. The ultimate outcome sought is a proven stroke care workflow for regional Australia, ready for deployment across Australia with the supporting technology. The clinical benefit and health economic data derived from this study is intended to provide a valuable role in driving emu™ product adoption and commercialisation.

EMVision intends to seek Australian regulatory clearance by leveraging prior FDA clearance, which expedites market launch. The Australian regulator, TGA, allows for abridged assessment of FDA cleared devices to reduce duplication in review. EMVision plans to seek market clearance once the in-progress pivotal trial (demonstrating diagnostic performance) has been completed.

Partners

The partners on the successful grant submission include Titan Pre-hospital Innovation, Australian Stroke Alliance and South Australian Rural Support Service. Titan Pre-hospital Innovation are responsible for the Zeus telehealth network, which will connect the emu™ brain scanner's output to expert neurologists at tertiary hospitals for clinical decision-making. The Australian Stroke Alliance will continue to provide EMVision with expert clinical guidance to ensure the study is conducted to the highest standard and that the research can translate into implementation. The South Australian Rural Support Service provide regional South Australian hospitals with capacity and capability to care for stroke patients, and within this study will provide staff and facilities to conduct the study. The project team has been assembled to ensure a robust and informative outcome, thanks to its extensive expertise in diagnostic technology, digital health, stroke systems of care, and regional healthcare.

Australian Stroke Alliance co-chair Professor Geoffrey Donnan commented: "The awarding of this grant reflects the strength of the collaboration between the Australian Stroke Alliance, Titan and EMVision in bringing cutting edge brain imaging technology to the patient. This will ultimately allow for the earlier treatment of stroke wherever the patient is located, and significant improvement in stroke patient outcomes."

EMVision's CEO Scott Kirkland commented: "We're thrilled to have secured this grant to support regional clinical studies with our emu™ point-of-care brain scanner. Generating high-quality clinical evidence is at the core of our commercial strategy, and this funding enables us to place emu™ directly into regional Australia, particularly in settings where timely stroke diagnosis and access to advanced imaging are limited. It's an exciting step toward improving stroke care where it's needed most."

The funding is subject to execution of grant agreements, including a funding agreement between the Commonwealth and EMVision.

Active Grant Program	Total Funding	Funding Remaining (as at 15 August 2025)
Australian Stroke Alliance	$8.0 million	$0.4 million
Industry Growth Program	$5.0 million	$4.0 million
Cooperative Research Centres Projects	$3.0 million	$3.0 million
Total	**$16 million**	**$7.4 million**

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investors & Media
+61 400 400 380
andrew.keys@keysthomas.com

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.